GENMAB A/S GNMSF news, videos and press releases
For more news please use our advanced search feature.
GENMAB A/S GNMSF - More news...
GENMAB A/S GNMSF - More news...
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Nine Months of 2021
- Genmab Improves its 2021 Financial Guidance
- Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
- Genmab to Present at Jefferies Virtual London Healthcare Conference
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
- Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
- Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
- Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
- Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Half of 2021
- Major Shareholder Announcement
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Completion of share buy-back program
- Transactions in connection with share buy-back program
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions in connection with share buy-back program
- Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
- Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
